Navigation Links
MetaStat, Inc. Executes Two New Licenses

THE WOODLANDS, Texas, April 27, 2012 /PRNewswire/ -- MetaStat, Inc. (OTCBB: MTST) announced today that it has executed two additional license agreements to patent applications and technology from the Albert Einstein College of Medicine of Yeshiva University. The first license agreement covers U.S. Patent Application No. 12/998,237 entitled "An In Vivo Quantitative Screening Test for Anti-Metastasis Treatment Efficacy"; inventors: Jeffrey Edward Segall, John S. Condeelis, Dmitriy Kedrin, Jacco van Rheenan and Bojanna Gligorijevic. The second license includes two areas of intellectual property, U.S. Patent Application No. 11/659,514 entitled "Isolation, Gene Expression, and Chemotherapeutic Resistance of Motile Cancer Cells"; inventor John S. Condeelis (and its accompanying Canadian and European Patent Applications) and U.S. Provisional Patent Application (pending) entitled "Human Invasion Signature for Prognosis of Metastatic Risk"; inventors: John S. Condeelis and Antonia Patsialou.

We believe the technologies covered in these patent applications expand MetaStat's intellectual property in the field of highly metastatic cells.  Metastatic cells are the cancer cells that have developed the ability to transform themselves both physically and behaviorally from proiferative to metastatic. They migrate within the tumor, hone in on the tumor vasculature, form complexes on the surface of the blood vessels, and gain entry to the blood stream where they are carried to distant organs and tissues of the body to form metastases. These distant site metastases are the cause of the vast majority of fatalities from solid tumor cancers including approximately 90% of fatalities from breast cancer.

We believe the technology underlying "An In Vivo Quantitative Screening Test for Anti-Metastasis Treatment Efficacy" is expected to provide drug developers at MetaStat and potential corporate partners with drug development tools to develop the next generation of anti-metastatic drugs. There are currently no FDA approved drugs to target and kill these metastatic cells.

"Isolation, Gene Expression, and Chemotherapeutic Resistance of Motile Cancer Cells" describes an "artificial blood vessel" that was developed to mimic the chemical attraction exerted on highly metastatic cells by the tumor vasculature. We believe this is the first method available to actually isolate, collect, genetically profile, and determine chemotherapeutic resistance of a pure population of metastatic cancer cells from a tumor. Previously, attempts to genetically profile these dangerous cells were difficult because tumor samples available for analysis contained large proportions of proliferative and structural cells and only a tiny proportion of metastatic cells.

"Human Invasion Signature for Prognosis of Metastatic Risk," another result of our proprietary ability to isolate metastatic cells, describes the actual causative gene signature of metastatic cells. This approach contrasts with currently available technology that purports to evaluate risk of cancer recurrence by relying upon correlative mathematical algorithms developed through the statistical analysis of whole tumor tissue samples.

About MetaStat, Inc.

MetaStat is a life science company focused on the development and commercialization of proprietary clinical diagnostic tests that predict the probability of systemic hematogenous (blood borne) metastasis of cancer, as well as companion therapeutics to prevent this deadly spread. We believe our initial product, the MetaSite Breast™ test, will predict the probability that cancer will be disseminated by this means to other organs in the body. MetaSite Breast is expected to be an important guide to treatment strategies for breast cancer patients and their doctors because metastasis is responsible for almost 90% of fatalities from breast cancer.  Further, the platform technology underlying this diagnostic approach may be applicable in up to 80% of all solid tumor cancers, including prostate, lung, colorectal, head and neck, and pancreatic.  Most significantly, we believe our platform technology provides us with targets of intervention in key pathways for the development of the first therapies that may preemptively reduce or eliminate metastasis thereby dramatically reducing fatalities.

Our technology platform and corresponding products result from over 15 years of collaboration involving four highly respected scientific institutions. We are unique and differentiated in the marketplace because our discoveries are based on direct microscopic visualization of living, functioning cancer tumors. We have observed the behaviors and mechanisms used by metastatic cells as they migrate to and penetrate blood vessels, where they are subsequently carried away to establish distant site metastases.

For More Information, Contact:

Warren C. Lau
President & CEO
MetaStat, Inc.
(281) 363-0003

SOURCE MetaStat, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. PhotoVoltaic Solar Cells, Inc. Completes Share Exchange with MetaStat, Inc.
2. MetaStat, Inc. Completes Share Exchange with PhotoVoltaic Solar Cells, Inc.
3. Ampio Pharmaceuticals Executes License and Development Agreement with Daewoong Co. Ltd. to Commercialize Zertane™ in South Korea
4. Adeona Executes Agreement to Initiate Phase IIb Clinical Trial of Proprietary Zinc-Based Therapy in Lou Gehrigs Disease (ALS)
5. Adeona Executes Manufacturing and Supply Agreement with TG United for reaZin™
6. Soligenix Executes Exclusive License with the University of Colorado for Vaccine Thermostabilization Technology
7. Alexza Executes $15 million Working Capital Loan with Hercules Technology Growth Capital, Inc.
8. Kun Run Biotechnology, Inc. Executes Purchase Agreements for Approximately $8 Million Private Placement
9. Obecure Executes Licensing and Clinical Supply Agreement With Farmaceutici-Formenti SPA for Extended Release Formulation of Betahistine
10. Transgenomic, Inc. Executes License Option agreement for Parkinsons Disease Diagnostic Markers with Gene Solutions, LLC
11. DOR BioPharma, Inc. Executes $400,000 Equity Investment Agreement With Numoda Corporation
Post Your Comments:
(Date:10/12/2015)... Oct. 12, 2015  CME Group,s Center for Innovation ... CEO of Theranos, is the 11 th recipient of ... the revolutionary blood diagnostics company, Theranos , to change ... in a new era of preventive care. CME Group will ... Leadership Conference in Naples, Florida , ...
(Date:10/12/2015)... , October 12, 2015 ... - Pipeline Review, H2 2015 market research report ... R&D pipelines by identifying new targets and MOAs ... . --> ... pipeline spread across 62 pages, analyzing 6 companies, ...
(Date:10/12/2015)... VALLEY COTTAGE, New York , October 12, 2015 /PRNewswire/ ... Market Insights (FMI) delivers key insights on the global vital ... Signs Monitoring Devices Market: Global Industry Analysis and Opportunity Assessment ... to expand at a healthy CAGR of 9.5% and 9.2% ... period, due to factors, regarding which FMI offers major insights ...
Breaking Medicine Technology:
(Date:10/13/2015)... ... October 13, 2015 , ... ActivePDF, a ... PDF automation tool to batch conversions of CAD drawings, plans, and diagrams ... fidelity. , CADConverter eliminates the complexity requirement of specialized applications to view CAD ...
(Date:10/13/2015)... ... October 13, 2015 , ... ... the world’s first commercially-available next-generation sequencing laboratory test for bacterial vaginosis- a ... and Obstetrics in Vancouver, BC, Canada. , In a presentation entitled: ...
(Date:10/12/2015)... ... October 13, 2015 , ... ... biannual Heroes in Recovery Awards at Foundations Recovery Network’s Moments of Change conference ... the one-of-a-kind awards to Noah Levine and Dean Dauphinais who exemplify the ideals ...
(Date:10/12/2015)... CA (PRWEB) , ... October 12, 2015 , ... According to an article ... data from adults today versus those of a similar group taken in 1988 has shown ... that a person in 2008 with the same diet as someone in 1971 would be ...
(Date:10/12/2015)... ... October 12, 2015 , ... Amerec , a leader in ... and skin care equipment, will be displaying custom sauna and steam room solutions at ... high-end resorts and spas as customers, SpaEquip is recognized for their ability to assist ...
Breaking Medicine News(10 mins):